Investors

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds

Webcast ImageWebcast
Q2 2015 AcelRx Pharmaceuticals, Inc. Earnings Conference Call (Live)
08/03/15 at 4:30 p.m. ET
Q2 2015 AcelRx Pharmaceuticals, Inc. Earnings Conference Call
Monday, August 3, 2015 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
PDF File ACRX Corporate Presentation - 5/7/15
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, Zalviso, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the complexity of infusion pumps. AcelRx has announced positive results from each of the three Phase 3 clinical trials for Zalviso and has submitted an NDA to the FDA seeking its approval. AcelRx also announced positive top-line results for a Phase 2 trial for ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, funded through a grant from U.S. Army Medical Research and Materiel Command. The company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development.
ACRX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$4.01
Change (%) Stock is Up 0.01 (0.25%)
Volume312,424
Data as of 07/29/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent News

    More >>
07/29/15AcelRx Pharmaceuticals to Hold Business Update and Second Quarter Financial Results Conference Call and Webcast on Monday, Aug. 3rd, 2015.
REDWOOD CITY, Calif., July 29, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release Second Quarter financial results after market close on Monday, Aug 3rd, 2015. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on Aug 3rd,... 
Printer Friendly Version
07/24/15AcelRx Announces Positive CHMP Opinion for Zalviso in the Management of Acute Moderate-to-Severe Post-Operative Pain in Adult Patients
REDWOOD CITY, Calif., July 24, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), has adopted a positive opinion for Zalviso™ (sufentanil sublingual tablets). The opinion, while not binding, recommends marketing authorization for Zalviso for the management of acute moderate-to-severe post-operative pain in adult patients. Zalviso is an investigational dru... 
Printer Friendly Version
07/02/15Zalviso™ Phase 3 Orthopedic Results Published In Anesthesiology Demonstrate Significant Reductions In Post-Operative Pain
Results indicate Zalviso controlled moderate-to-severe acute pain following orthopedic surgery better than placebo, with similar side effect profile REDWOOD CITY, Calif., July 2, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that results from the IAP311 study have been published in Anesthesiology.  IAP... 
Printer Friendly Version

Upcoming Events

    More >>
DateTitle
08/03/15 4:30 p.m. ET
Q2 2015 AcelRx Pharmaceuticals, Inc. Earnings Conference Call
09/09/15
AcelRx Pharmaceuticals, Inc. at the Rodman & Renshaw 17th Annual Global Investment Conference
LocationSt. Regis Hotel
New York, NY
09/09/15
AcelRx Pharmaceuticals, Inc. at the FBR Second Annual Healthcare Conference
LocationFour Seasons Hotel
Boston, MA

Receive E-mail Alerts 

Sign up to receive e-mail alerts whenever AcelRx Pharmaceuticals, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

AcelRX

CONTACT